Traws Pharma (TRAW) 10-K2019 FY Annual report

Filed: 27 Mar 20, 4:26pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ab, Abraham, abstract, Abundant, accident, Agremeent, al, allotted, appeal, arm, assignee, Australia, billion, biosimilar, borrowing, CAD, Cadillac, Canada, Captial, communicable, Congressional, constitutionality, Counsel, cybersecurity, database, deadline, Description, downturn, draft, driven, EC, electronic, escrow, evolving, exhausted, facilitate, Helathcare, Hong, implicit, Incoporated, initio, Israel, journal, Kingdom, Knight, Kong, left, likelihood, Macau, magnitude, master, mutated, nivolumab, Oler, outbreak, owed, paving, penalize, plant, portal, Pte, reassessed, reassessing, rhabdomyosarcoma, ROFR, ROU, rulemaking, sensitive, software, Specialised, spread, Squibb, STA, step, store, strain, Taiwan, takedown, theCompany, unreasonable, void, widespread, withheld, Zealand

Removed: absent, added, amounting, automatic, bargaining, Baxalta, Baxter, beneficially, capita, citing, coincide, collective, conversion, devoted, doubt, Dr, exceeding, explanatory, explore, feel, inactive, IPAB, Lincoln, merger, minimal, Obama, optimization, organizational, Park, paused, placebo, predecessor, prevailing, propose, ratio, recommend, Regular, replacement, resale, simultaneously, Taxpayer, trillion, unsolicited, vast, version

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated TRAW transcripts

TRAW similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

QuickLinks -- Click here to rapidly navigate through this document

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1): Registration Statement (Form S-8 No. 333-191161) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(2): Registration Statement (Form S-8 No. 333-194228) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(3): Registration Statement (Form S-8 No. 333-204210) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(4): Registration Statement (Form S-8 No. 333-210694) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(5): Registration Statement (Form S-8 No. 333-215575) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(6): Registration Statement (Form S-8 No. 333-222400) pertaining to the Onconova Therapeutics, Inc. 2013 Equity Compensation Plan
(7): Registration Statement (Form S-8 No. 333-226199) pertaining to the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan
(8): Registration Statement (Form S-8 No. 333-233410) pertaining to the Onconova Therapeutics, Inc. 2018 Omnibus Incentive Compensation Plan
(9): Registration Statement (Form S-3 No. 333-230744) of Onconova Therapeutics, Inc.
(10): Registration Statement (Form S-3 No. 333-221684) of Onconova Therapeutics, Inc.
(11): Registration Statement (Form S-1 No. 333-211769) of Onconova Therapeutics, Inc.
(12): Registration Statement (Form S-1 No. 333-222374) of Onconova Therapeutics, Inc.
(13): Registration Statement (Form S-1 No. 333-224315) of Onconova Therapeutics, Inc.
(14): Registration Statement (Form S-1 No. 333-234360) of Onconova Therapeutics, Inc.

of our report dated March 27, 2020, with respect to the consolidated financial statements of Onconova Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.


		/s/ Ernst & Young LLP
Philadelphia, Pennsylvania March 27, 2020

QuickLinks

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.